Xtl Biopharmaceuticals XTLB

XTL Biopharmaceuticals Ltd is an intellectual property based company engaged in the development, management, and commercialization of intellectual property. The company operates in two primary business areas: biopharmaceuticals through its license for hCDR1 and AI web data collection through its wholly owned subsidiary The Social Proxy Ltd.

XTL Biopharmaceuticals Ltd generates revenue primarily through licensing agreements and data collection services. The company earns revenue from its exclusive sublicense agreement with Biossil Inc. for the hCDR1 peptide, which includes potential milestone payments upon regulatory and commercial achievements. Additionally, revenue is generated from The Social Proxy Ltd.'s provision of ethical proxy services and data collection solutions, including 5G and 4G mobile private proxies, dedicated and rotating proxy services, and API-driven data extraction tools for AI and business intelligence applications.

The company operates through the following segments: biopharmaceutical intellectual property and AI web data collection and proxy services.

• The biopharmaceutical intellectual property segment involves the licensing and potential commercialization of hCDR1, a novel synthetic peptide for the treatment of systemic lupus erythematosus and Sjogren’s syndrome, based on exclusively licensed patents from Yeda Research and Development Company Ltd.
• The AI web data collection and proxy services segment, operated through The Social Proxy Ltd., provides ethical, secure, and scalable proxy solutions using proprietary 5G and 4G mobile private proxies, in-house hardware and software, and AI-powered data extraction tools such as the Professional Data API, Social Scraper API, and SERP API to enable businesses to collect and analyze web data at scale while complying with privacy regulations.

XTL Biopharmaceuticals Ltd holds a niche position in both the biopharmaceutical and data collection industries. In biopharmaceuticals, the company leverages its exclusive license for hCDR1, a potential treatment for autoimmune diseases, though it has sublicensed development and commercialization rights to Biossil. In the data collection and proxy services market, The Social Proxy differentiates itself through its ethical open web data collection platform, ownership of hardware and IP addresses, and use of Carrier-Grade Network Address Translation technology, competing against established players like Bright Data, Oxylabs, Smartproxy, and NetNut by emphasizing compliance, speed, and ethical sourcing of proxy networks.

The company serves businesses and organizations requiring ethical and compliant web data collection for AI, business intelligence, and cybersecurity purposes, including enterprises in finance, e-commerce, healthcare, and technology sectors that rely on large-scale data extraction for model training, market analysis, and competitive intelligence while adhering to regulations such as GDPR and CCPA.